Technical Data
BTLA (B- and T-lymphocyte Associated Protein, B- and T-lymphocyte Attenuator, BTLA1, CD272, CD272 Antigen, FLJ16065, MGC129743) (PE)
Human CD272 (BTLA, B and T Lymphocyte Attenuator) is a member of the Immunoglobulin superfamily and has sequence homology to PD-1 and CTLA4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand, CD270 (HVEM, a TNF superfamily member) can down regulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines (1). Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis (3).

Suitable for use in FLISA and Flow Cytometry. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C before opening. DO NOT FREEZE! Stable at 4C as an undiluted liquid. Dilute only prior to immediate use. Stable for 12 months at 4C. Freezing R-Phycoerythrin (PE) conjugates will result in a substantial loss of activity. PE conjugates are sensitive to light.
MabIgG1,k11K2Affinity Purified
120Tests4C Do Not FreezeBlue IceHumanMouse
As reported
Recombinant corresponding to soluble human CD272.
Purified by Protein A affinity chromatography.
Supplied as a liquid in 50mM sodium phosphate, pH 7.5, 100mM potassium chloride, 150mM sodium chloride, 0.2% BSA, 0.04% sodium azide, 5% glycerol. Labeled with R-Phycoerythrin (PE).
Recognizes human CD272. Binds to CD272 on the cell surface of human PBMC in Flow cytometry and to recombinant CD272-muIg in EIA. Blocks binding of Biotinylated CD270(HVEM)-muIg to CD272-muIg in EIA.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Derre L, DE Speiser, et al. (2010) J Clin Invest 120(1):157-167, 2. Otsuki N, Azuma M, et al. (2006) Biochem Biophys Res Com 344(4): 1121-1127, 3. Lin SC, Chan CH, et al. (2006) J Biomed Sci 13(6): 853-860, 4. Pasero C, D Olive, et al. (2009) Curr Mol Med 9(7): 911-927, 5. Gavrieli M, KM Murphy, et al. (2006) Adv Immunol 92: 152-185.